# Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

Study · id `cardio:ct-nct03718559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03718559](<https://clinicaltrials.gov/study/NCT03718559>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03718559

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1040 participants.

## Technical summary

Registry record NCT03718559. Randomized; no masking; primary purpose treatment. Start 2019-05-14 (actual); primary completion 2023-11-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1040 participants (enrolled count; ClinicalTrials.gov record NCT03718559, source copy `cardio:ctgov-nct03718559-2024-06-10`, retrieved 2026-10-26)
- Started: 2019-05-14 (actual) (ClinicalTrials.gov record NCT03718559, source copy `cardio:ctgov-nct03718559-2024-06-10`, retrieved 2026-10-26)
- Primary completion: 2023-11-08 (actual) (ClinicalTrials.gov record NCT03718559, source copy `cardio:ctgov-nct03718559-2024-06-10`, retrieved 2026-10-26)
- Completion: 2023-11-08 (actual) (ClinicalTrials.gov record NCT03718559, source copy `cardio:ctgov-nct03718559-2024-06-10`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03718559, source copy `cardio:ctgov-nct03718559-2024-06-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03718559-2024-06-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
- Acronym: EPIC-CAD
- Condition: Atrial Fibrillation
- Condition: Coronary Artery Disease
- Condition: Stable Angina
- Condition: Stable Chronic Angina
- Intervention (Drug): Edoxaban Monotherapy
- Intervention (Drug): Edoxaban plus Single Antiplatelet Agent
- Lead sponsor: Gi-Byoung Nam
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease (`cardio:pubmed-39225258`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Off-label underdosing of edoxaban antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease: findings from the EPIC-CAD trial (`cardio:pubmed-40930594`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial (`cardio:pubmed-41848064`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of renal function on edoxaban antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease: a prespecified analysis of the EPIC-CAD trial (`cardio:pubmed-42003300`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban antithrombotic therapy in diabetic patients with atrial fibrillation and stable coronary artery disease: the EPIC-CAD trial (`cardio:pubmed-42690164`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2deba71b9b314a7e309832adbccbd67fdf98d934c2bbc2dcd10e81d1136ae007
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
